Renoprotective effects of pirfenidone on chronic renal allograft dysfunction by reducing renal interstitial fibrosis in a rat model-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Renoprotective effects of pirfenidone on chronic renal allograft dysfunction by reducing renal interstitial fibrosis in a rat model

Published:2019-09 Issue: Volume:233 Page:116666
ISSN:0024-3205
Container-title:Life Sciences
language:en
Short-container-title:Life Sciences

Author:

Qiu Zhen-Zhen,He Ji-Ming,Zhang Hao-Xiang,Yu Zuo-Hua,Zhang Zhi-Wei,Zhou Hao

Funder

National Natural Science Foundation of China

Natural Science Foundation of Fujian Province

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference34 articles.

1. Chronic renal allograft dysfunction in Egyptian population: histopathological and immunohistochemical study;Hamza;Saudi J. Kidney Dis. Transpl.,2016

2. Expression and significance of RANTES and MCP-1 in renal tissue with chronic renal allograft dysfunction;Yan;Transplant. Proc.,2016

3. Regulatory T cell subtypes and TGF-beta1 gene expression in chronic allograft dysfunction;Assadiasl;Iran. J. Immunol.,2014

4. Expression of GSK-3beta in renal allograft tissue and its significance in pathogenesis of chronic allograft dysfunction;Yan;Diagn. Pathol.,2012

5. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis;King;N. Engl. J. Med.,2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pirfenidone ameliorates ANIT-induced cholestatic liver injury via modulation of FXR, NF-кB/TNF-α, and Wnt/GSK-3β/β-catenin signaling pathways;Toxicology and Applied Pharmacology;2024-09

2. Pirfenidone inhibits TGF-β1-induced fibrosis via downregulation of Smad and ERK pathway in MDCK cells;Veterinary Research Communications;2024-08-12

3. Pirfenidone inhibits TGF-β1-induced fibrosis via downregulation of Smad and ERK pathway in MDCK cells;2024-07-03

4. Pirfenidone use in fibrotic diseases: What do we know so far?;Immunity, Inflammation and Disease;2024-07

5. Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets;Journal of Clinical Medicine;2024-03-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3